Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

Open access
Brendel, Matthias, Barthel, Henryk, van Eimeren, Thilo, Marek, Ken, Beyer, Leonie, Song, Mengmeng, Palleis, Carla, Gehmeyr, Mona, Fietzek, Urban, Respondek, Gesine, Sauerbeck, Julia, Nitschmann, Alexander, Zach, Christian, Hammes, Jochen, Barbe, Michael T., Onur, Oezguer, Jessen, Frank, Saur, Dorothee, Schroeter, Matthias L., Rumpf, Jost-Julian, Rullmann, Michael, Schildan, Andreas, Patt, Marianne, Neumaier, Bernd, Barret, Olivier, Madonia, Jennifer, Russell, David S., Stephens, Andrew, Roeber, Sigrun, Herms, Jochen, Bötzel, Kai, Classen, Joseph, Bartenstein, Peter, Villemagne, Victor, Levin, Johannes, Höglinger, Günter U., Drzezga, Alexander, Seibyl, John, Sabri, Osama·2020·JAMA Neurology

Abstract

Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis. Objective: To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP. Design, Setting, and Participants: In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (including those with Richardson syndrome [RS]) according to Movement Disorder Society PSP criteria were examined together with healthy controls and controls with disease. Four additionally referred individuals with PSP-RS and 2 with PSP-non-RS were excluded from final data analysis owing to incomplete dynamic PET scans. Data were collected from December 2016 to October 2019 and were analyzed from December 2018 to December 2019. Main Outcomes and Measures: Postmortem autoradiography was performed in independent PSP-RS and healthy control samples. By in vivo PET imaging, 18F-PI-2620 distribution volume ratios were obtained in globus pallidus internus and externus, putamen, subthalamic nucleus, substantia nigra, dorsal midbrain, dentate nucleus, dorsolateral, and medial prefrontal cortex. PET data were compared between patients with PSP and control groups and were corrected for center, age, and sex. Results: Of 60 patients with PSP, 40 (66.7%) had RS (22 men [55.0%]; mean [SD] age, 71 [6] years; mean [SD] PSP rating scale score, 38 [15]; score range, 13-71) and 20 (33.3%) had PSP-non-RS (11 men [55.0%]; mean [SD] age, 71 [9] years; mean [SD] PSP rating scale score, 24 [11]; score range, 11-41). Ten healthy controls (2 men; mean [SD] age, 67 [7] years) and 20 controls with disease (of 10 [50.0%] with Parkinson disease and multiple system atrophy, 7 were men; mean [SD] age, 61 [8] years; of 10 [50.0%] with Alzheimer disease, 5 were men; mean [SD] age, 69 [10] years). Postmortem autoradiography showed blockable 18F-PI-2620 binding in patients with PSP and no binding in healthy controls. The in vivo findings from the first large-scale observational study in PSP with 18F-PI-2620 indicated significant elevation of tracer binding in PSP target regions with strongest differences in PSP vs control groups in the globus pallidus internus (mean [SD] distribution volume ratios: PSP-RS, 1.21 [0.10]; PSP-non-RS, 1.12 [0.11]; healthy controls, 1.00 [0.08]; Parkinson disease/multiple system atrophy, 1.03 [0.05]; Alzheimer disease, 1.08 [0.06]). Sensitivity and specificity for detection of PSP-RS vs any control group were 85% and 77%, respectively, when using classification by at least 1 positive target region. Conclusions and Relevance: This multicenter evaluation indicates a value of 18F-PI-2620 to differentiate suspected patients with PSP, potentially facilitating more reliable diagnosis of PSP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2020.2526

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 264

Metadata

Authors
Brendel, M., Barthel, H., van Eimeren, T., Marek, K., Beyer, L., Song, M., Palleis, C., Gehmeyr, M., Fietzek, U., Respondek, G., Sauerbeck, J., Nitschmann, A., Zach, C., Hammes, J., Barbe, M. T., Onur, O., Jessen, F., Saur, D., Schroeter, M. L., Rumpf, J.-J., Rullmann, M., Schildan, A., Patt, M., Neumaier, B., Barret, O., Madonia, J., Russell, D. S., Stephens, A., Roeber, S., Herms, J., Bötzel, K., Classen, J., Bartenstein, P., Villemagne, V., Levin, J., Höglinger, G. U., Drzezga, A., Seibyl, J., & Sabri, O.
Venue
JAMA Neurology
Published
2020-11-01
Volume
77
Issue
11
Pages
1408
ISSN
2168-6149 (ISSN-L)
OpenAlex
W3038832112
Cited by
264
References
30
FWCI
13.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. https://app.cochat.ai/papers/10.1001/jamaneurol.2020.2526
The paper
Brendel, M., Barthel, H., van Eimeren, T., Marek, K., Beyer, L., Song, M., Palleis, C., Gehmeyr, M., Fietzek, U., Respondek, G., Sauerbeck, J., Nitschmann, A., Zach, C., Hammes, J., Barbe, M. T., Onur, O., Jessen, F., Saur, D., Schroeter, M. L., . . . Sabri, O. (2020). Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2020.2526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.